By Shannon Benton, Executive Director, TSCL 

Prescription drug costs remain one of the biggest financial concerns facing older Americans. That’s why The Senior Citizens League (TSCL) recently submitted formal comments to the Centers for Medicare & Medicaid Services (CMS) supporting continued implementation of Medicare’s Drug Price Negotiation Program. 

For decades, the law largely prevented  Medicare from directly negotiating the prices of prescription drugs covered under Part D. Recent changes in federal law have begun to change that, giving Medicare the ability to negotiate prices for certain high-cost medications. 

TSCL believes that is an important step toward bringing prescription drug costs under control. 

Drug Costs Continue to Climb 

The numbers show why we need action. 

Prescription drug prices in 2024 were about 5.5 times higher than in 1985, rising about three times as fast as overall inflation. Meanwhile, U.S. prescription drug spending increased 7.9 percent in 2024, reaching approximately $467 billion. 

The problem will soon become even more expensive for Medicare. Medicare Part D spending is projected to nearly double, from approximately $181 billion in 2025 to $346 billion in 2035. 

For seniors already struggling with premiums, copays, deductibles, groceries, housing, utilities, and other everyday expenses, continually rising drug costs add yet another burden to already strained household budgets. 

Lower Prices Help Seniors—and Medicare 

Medicare drug price negotiation isn’t only about what beneficiaries pay at the pharmacy counter. Controlling prescription drug spending can also help reduce Medicare’s rapidly growing costs. 

Medicare Part D is financed through beneficiary premiums and federal government contributions. As Part D expenses rise, beneficiaries and taxpayers must provide additional funding. 

Allowing Medicare to negotiate lower prices gives the program another tool to control those costs. 

CMS estimates that negotiated prices for the first group of selected drugs could save Medicare beneficiaries approximately $1.5 billion in out-of-pocket costs in the first year alone. 

For TSCL, that represents meaningful progress. 

The Pharmaceutical Industry Can Afford to Negotiate 

The pharmaceutical industry has argued that government price negotiations could reduce the money available to develop new medicines. 

TSCL believes those claims deserve scrutiny. 

Pharmaceutical companies spend enormous amounts on marketing and advertising. In 2024 alone, the industry spent more than $5 billion on television advertising and nearly $20 billion on digital advertising. 

At the same time, some of the world’s largest pharmaceutical companies continue to generate tens of billions of dollars in annual revenue. 

TSCL does not believe seniors should be asked to pay unnecessarily high prices for medications simply to protect pharmaceutical industry profits. 

Drug companies should be able to earn a reasonable return and continue investing in new treatments. But Medicare should also be able to negotiate a fair price on behalf of the millions of Americans whose healthcare dollars help support the industry. 

Seniors Deserve a Fair Deal 

Older Americans shouldn’t have to choose between filling a prescription and paying for groceries, housing, utilities, or other necessities. 

Medicare is one of the country’s largest healthcare purchasers. Giving it the ability to negotiate prices for certain expensive prescription drugs is a common-sense way to use that purchasing power on behalf of beneficiaries and taxpayers. 

That’s why TSCL has urged CMS to move forward with its proposed regulations and continue implementing Medicare drug price negotiation. 

The pharmaceutical industry has enormous resources and a powerful voice in Washington. America’s seniors deserve one, too. 

TSCL will continue fighting to make sure they have it.